Clinigen Group and United Therapeutics Initiate Managed Access Program for UNITUXIN™ (Dinutuximab) Injection for High Risk Neuroblastoma
Clinigen Group plc’s (AIM: CLIN, ‘Clinigen’ or the ‘Group’) Idis Managed Access (MA) division and United Therapeutics Corporation (‘United Therapeutics’), a biotechnology company focused on the development and commercialization of products for chronic and... - November 06, 2015
HAEi Global Access Program for RUCONEST® Now Live
Unique patient organization-driven program is enabling people with Hereditary Angioedema (HAE) who cannot access effective treatments to receive medication for the first time - July 23, 2015
Clinigen Group Appointed as Specialist Partner to Manage Global Access Program for Clovis Oncology’s Rociletinib
Clinigen Group announce the initiation of a global access program in Europe for Clovis Oncology's rociletinib (CO-1686) which is being developed for the treatment of advanced non-small cell lung cancer (NSCLC). - May 30, 2015
Clinigen Group and Pharming Initiate “HAEi GAP” Global Access Program for RUCONEST®
Unique patient organization-driven program will enable patients with hereditary angeoedema (HAE) who cannot access effective treatments to receive medication for the first time. - May 21, 2015
Clinigen Group Adds New Named Patient Program to Global Access Portfolio
Clinigen Group announces the latest program to be managed by Clinigen Global Access Programs (Clinigen GAP). The program will provide access to Raptor Pharmaceuticals Corp.’s PROCYSBI® (cysteamine bitartrate) for individual patients with nephropathic cystinosis. - February 20, 2015
Clinigen Appointed by AstraZeneca to Manage International Global Access Program for New Combination Antibiotic, CAZ-AVI
Clinigen Group plc announce the initiation of an international global access program for AstraZeneca’s investigational antibiotic, CAZ-AVI (ceftazidame-avibactam), through its specialist Clinigen GAP division. CAZ-AVI is being developed to treat a broad range of Gram-negative bacterial infections which are becoming resistant to antibiotics and pose an increasing risk to public health. - February 13, 2015
New ISPE White Paper Provides Guidance on Development and Implementation of Regulatory-Compliant Patient Access Programs
Panel of industry experts chaired by SVP Clinigen Global Access Programs offers best practices for programs enabling access for patients with unmet medical needs. - August 09, 2014
Clinigen Group to Manage International Named Patient Program for Abiogen Pharma’s Nerixia® (Neridronic Acid)
Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) and Abiogen Pharma SpA (‘Abiogen’) jointly announced today the initiation of a Named Patient Program, managed by Clinigen Global Access Programs (Clinigen GAP) to provide Nerixia® (neridronic acid),... - April 16, 2014